

100. Chen C, Kourouk CT, White D, et al. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma*. 2009;9:74-76.
101. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. *Am J Hematol*. 2010;85:670-674.
102. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. *Blood*. 2018;132:2608-2612.
103. Gavriatopoulou M, Garcia-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. *Blood*. 2017;129:456-459.
104. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood*. 2013;122(19):3276-3282. doi: 10.1182/blood-2013-05-503862.
105. Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. *Blood*. 2018;132:547-550.
106. Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited: a multinational observational study of 232 patients. *Blood*. 2022;136(4):480-488.
107. Kong D, Li Y, Fu C, Hou M, Yan L. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. *Leuk Lymphoma*. 2022;63(2):491-494. doi: 10.1080/10428194.2021.1992766. Epub 2021 Oct 20. PMID: 34668450.
108. Ojeda-Urbe M, Rimelén V, Marzullo C. Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome. *J Blood Med*. 2020;11:67-72. doi: 10.2147/JBM.S233059. PMID: 32104129; PMCID: PMC7025649.
109. Zhang YP, Yang X, Lin ZH, Wang XF, Cao X, You XF, Huang HM, Shi WY, Liu H. Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenström macroglobulinemia. *Eur J Haematol*. 2017;99(6):489-494. doi: 10.1111/ejh.12935. Epub 2017 Sep 13. PMID: 28801984.
110. Leblond V, Morel P, Dillhuyd MS. French Innovative Leukemia Organization (FILO). A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. *Leuk Lymphoma*. 2017;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357.
111. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. *Blood*. 2014;124(4):503-510. doi: 10.1182/blood-2014-03-566273.
112. Vesole DH, Richter J, Biran N, et al. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. *Leuk Lymphoma*. 2018;59(1):259-261. doi: 10.1080/10428194.2017.1321749.
113. Chaudhry M, Steiner R, Claussen C, et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstrom's macroglobulinemia. *Leuk Lymphoma*. 2019;60:964-970.
114. Castillo JJ, Meid K, Catherine A, et al. Ixazomib, dexamethasone, and rituximab in treatment-naïve patients with Waldenström macroglobulinemia: long-term follow-up. *Blood Adv*. 2020;4(16):3952-3959. doi: 10.1182/bloodadvances.2020001963.
115. Kersten MJ, Amaador K, Minnema MC, et al. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. *J Clin Oncol*. 2022;40(1):40-51. doi: 10.1200/JCO.21.00105.
116. Ma W, Zhao J, Zhang L. A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia. *Turk J Haematol*. 2021;38(1):87-89. doi: 10.4274/tjh.galenos.2020.2020.0521.
117. Kastritis E, Dimopoulos MA. Proteasome Inhibitors in Waldenström Macroglobulinemia. *Hematol Oncol Clin North Am*. 2018;32(5):829-840. doi:10.1016/j.hoc.2018.05.011.
118. Fečková-Mihályová J, Ďuraš J, Zuchnická J, et al. Ibrutinib v hematologii. *Klinická farmakologie a farmacie*. 2016;30(3):8-14.
119. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. *N Engl J Med*. 2015;372:1430-1440.
120. Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with Ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. *Clin Lymphoma Myeloma Leuk*. 2017;17:31-37.
121. Gustine JN, Meid K, Dubeau T, et al. Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound. *Am J Hematol*. 2018;93: 511-517.
122. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenström's macroglobulinemia. *N Engl J Med*. 2015;373:584-586.
123. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinemia. (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncol*. 2017;18:241-250.
124. Treon SP, Gustine J, Meid K, et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenström's macroglobulinemia. *Blood*. 2017;130:2767-2767.
125. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. *J Clin Oncol*. 2018;36(27):2755-2761.
126. Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinemia: practice patterns, toxicities and outcomes. *Br J Haematol*. 2020;188:394-403.
127. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenström's macroglobulinemia. *N Engl J Med*. 2018;378:2399-2410.
128. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iINNOVATE Study. *J Clin Oncol*. 2022;40(1):52-62. doi: 10.1200/JCO.21.00838.
129. Castillo JJ, Gustine JN, Meid K, et al. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. *Haematologica*. 2018;103:e466-e468.
130. Castillo JJ, Gustine JN, Meid K, et al. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. *Haematologica*. 2018;103:e307-e310.
131. Migkou M, Fotiou D, Gavriatopoulou M, et al. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. *Expert Opin Drug Saf*. 2021;20(9):987-995. doi: 10.1080/14740338.2021.1945031.
132. Castillo JJ, Abeykoon JP, Gustine JN, et al. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinemia patients treated with ibrutinib. *Br J Haematol*. 2021;192(3):542-550. doi: 10.1111/bjh.17225.
133. Castillo JJ, Meid K, Gustine JN, et al. Treon SP. Long-term follow-up of ibrutinib monotherapy in treatment-naïve patients with Waldenström macroglobulinemia. *Leukemia*. 2022;36(2):532-539. doi: 10.1038/s41375-021-01417-9.
134. Castillo JJ, Sarosiek SR, Gustine JN, et al. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. *Blood Adv*. 2022;6(3):1015-1024. doi: 0.1182/bloodadvances.2021006106.PMID: 34965304.
135. Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. *J Clin Oncol*. 2021;39(6):565-575. doi: 10.1200/JCO.20.00555.
136. Trotman J, Buske C, Tedeschi A, et al. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III iINNOVATE Trial. *Clin Cancer Res*. 2021;27(21):5793-5800. doi: 10.1158/1078-0432.CCR-21-1497.
137. Paydas S. Management of adverse effects/toxicity of ibrutinib. *Crit Rev Oncol Hematol*. 2019;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001.
138. Ganatra S, Sharma A, Shah S, et al. Ibrutinib-Associated Atrial Fibrillation. *JACC Clin Electrophysiol*. 2018;4(12):1491-1500. doi: 10.1016/j.jacep.2018.06.004.
139. Abbas HA, Wierda WG. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. *Front Oncol*. 2021;11:668162. doi: 10.3389/fonc.2021.668162. eCollection 2021.
140. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. *Lancet Haematol*. 2020;7(2):e112-e121.
141. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. *Blood*. 2020;136(18):2038-2050. doi: 10.1182/blood.2020006844.
142. Tam CS, LeBlond V, Novotny W, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. *Future Oncol*. 2018;14(22):2229-2237. doi: 10.2217/fon-2018-0163.
143. Dimopoulos M, Sanz RG, Lee HP, Trněný M, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. *Blood Adv*. 2024;4(23):6009-6018. doi: 10.1182/bloodadvances.2020003010.
144. Argyropoulos KV, Palomba ML. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. *Hematol Oncol Clin North Am*. 2018;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012.
145. Munakata W, Tobinai K. Tirabrutinib hydrochloride for B-cell lymphomas. *Drugs Today (Barc)*. 2021;57(4):277-289. doi: 10.1358/dot.2021.57.4.3264113.
146. Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax in Previously Treated Waldenström Macroglobulinemia. *J Clin Oncol*. 2022;40(1):63-71. doi: 10.1200/JCO.21.01194.
147. Novák J, Havrdá K, Gahérová L, et al. Clinical case: idelalisib-induced immunoglobulin flare. *Immunopharmacology and immunotoxicology*. 2017;39(4):251-255.
148. Belada D. Idelalisib v léčbě pacientů s folikulárním lymfomem. *Farmakoterapie*. 2015;11(3):292-296.
149. Kyriakou C. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia. *Hematol Oncol Clin North Am*. 2018;32(5):865-874. doi: 10.1016/j.hoc.2018.05.013.
150. Kašćák M, Ďuraš J, Navrátil M, et al. Autologní transplantace kmenových buněk u Waldenströmovy makroglobulinemie. *Transfúze a hematologie dnes*. 2016;22(1):28-38.
151. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. *Blood*. 2009;113:4163-4170.
152. Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. *Leukemia*. 2019;33(11):2654-2656.
153. Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinemia-A British Society for Haematology guideline. *Br J Haematol*. 2022;197(2):171-187. doi: 10.1111/bjh.18036.
154. Migkou M, Fotiou D, Gavriatopoulou M, et al. Ibrutinib plus rituximab for the treatment of adult patients